Erudio Healtherudio.com
Breast congress
ESMO Breast Cancer 2027
May 12–14, 2027 · Milan, Italy
Starts in 182 days
- Today · Nov 11
- May 12–14Meeting
- May 21First reports likely
- Dates
- May 12–14, 2027Central European Time (Milan)
- Website
- esmo.org ↗
- On X
- #ESMOBreast27
- Organiser
- European Society for Medical Oncology (ESMO)
- Calendar
- Add to calendar
Trials at ESMO Breast 2027
No trial is placed here yet.
A trial is listed only when at least two public sources, from two different publishers, place its results or presentation at ESMO Breast Cancer 2027; each row says how many did.
Follow #ESMOBreast27 on X ↗ for the first mentions.
What happens next
- May 12–14: the meeting; the list fills as clinicians talk about it.
- After: reports on the trials discussed, every statement linked to its source.
Breast reports so far
The newest published reports on breast trials from other congresses.
- ESMO 2026FOURLIGHT-1atirmociclib (PF-07220060) plus fulvestrant · HR-positive/HER2-negative advanced/metastatic breast cancer after CDK4/6 inhibitor-based therapy100 statements · 51 sources
- ESMO 2026APEX-Breast01TQB2102 · HER2 low-expressing recurrent/metastatic breast cancer40 statements · 12 sources
- ASCO 2026PANKU-Breast02izalontamab brengitecan (BL-B01D1) · unresectable locally advanced or metastatic triple-negative breast cancer125 statements · 28 sources
Editions
| Edition | Dates | City |
|---|---|---|
| ESMO Breast 2027this page | May 12–14, 2027 | Milan |
| ESMO Breast 2026 | May 6–8, 2026 | Berlin |
| ESMO Breast 2025 | May 14–17, 2025 | Munich |
| ESMO Breast 2024 | May 15–17, 2024 | Berlin |
| ESMO Breast 2023 | May 11–13, 2023 | Berlin |
| ESMO Breast 2022 | May 3–5, 2022 | Berlin |
| ESMO Breast 2021 | May 5–8, 2021 | Virtual |
| ESMO Breast 2020 | May 23–24, 2020 | Virtual |
| ESMO Breast 2019 | May 2–4, 2019 | Berlin |
Next on the calendar
| Congress | Dates | City |
|---|---|---|
| ASCO 2027 | Jun 4–8 | Chicago |
| EHA 2027 | Jun 10–13 | Barcelona |
| ICML 2027 | Jun 15–19 | Lugano |
How a trial gets on this page
A trial is listed only when at least two public sources, from two different publishers, place its results or presentation at ESMO Breast Cancer 2027; each row says how many did. The list is rebuilt every six hours.Reports
Focused$750Standard$1,250Deep$1,950Pricing
Priced by size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Organised by European Society for Medical Oncology (ESMO); Erudio is not affiliated with it.